History | Ozanimod for treating relapsing–remitting multiple sclerosis | Guidance | NICE

History

Documents created during the development process.

Expected publication

Register of interests (PDF 149 KB)

Published:

09 June 2021
Equality Impact Assessment (Guidance development) (PDF 136 KB)

Published:

09 June 2021

Final draft guidance: 1

Final draft guidance: 1
Committee papers Slides (PDF 1.01 MB)

Published:

13 May 2021
Final appraisal document (PDF 255 KB)

Published:

13 May 2021
Committee papers (PDF 1.85 MB)

Published:

13 May 2021
Assessment report EIA (PDF 136 KB)

Published:

13 May 2021

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) (PDF 259 KB)

Published:

22 January 2021
Appraisal consultation document (online commenting)
Committee papers (PDF 4.85 MB)

Published:

25 January 2021
Public committee slides (PDF 1.17 MB)

Published:

25 January 2021

Invitation to participate

Equality Impact Assessment (Guidance development) (PDF 121 KB)

Published:

02 September 2019
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 537 KB)

Published:

02 September 2019
Final scope (PDF 204 KB)

Published:

02 September 2019
Final stakeholder list (PDF 297 KB)

Published:

30 March 2021

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope pre referral (PDF 365 KB)

Published:

06 February 2018
Draft matrix pre referral (PDF 254 KB)

Published:

06 February 2018